NYSE American - Delayed Quote USD

Matinas BioPharma Holdings, Inc. (MTNB)

0.1789 -0.0026 (-1.43%)
At close: 4:00 PM EDT
0.1793 +0.00 (+0.22%)
After hours: 7:03 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Jerome D. Jabbour J.D. Co-Founder, CEO, President & Director 842.38k -- 1974
Dr. Theresa Matkovits Ph.D. Chief Development Officer 570.08k -- 1967
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer 621k -- 1954
Mr. Keith A. Kucinski CPA, M.B.A. Chief Financial Officer 249.05k -- 1970
Dr. Hui Liu M.B.A., Ph.D. Chief Technology Officer -- -- 1968
Mr. Frank Calamusa Executive Director and Head of Manufacturing & Supply Chain -- -- --
Mr. Thomas J. Hoover M.B.A. Chief Business Officer -- -- 1970

Matinas BioPharma Holdings, Inc.

1545 Route 206 South
Suite 302
Bedminster, NJ 07921
United States
908 484 8805 https://www.matinasbiopharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
32

Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Corporate Governance

Matinas BioPharma Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Matinas BioPharma Holdings, Inc. Earnings Call

Related Tickers

KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
TOVX Theriva Biologics, Inc.
0.4195
+2.33%
 
NBY NovaBay Pharmaceuticals, Inc.
0.0788
+2.34%
 
KZR Kezar Life Sciences, Inc.
0.8049
+1.89%
 
RNAZ TransCode Therapeutics, Inc.
0.5499
+5.30%
 
EQ Equillium, Inc.
1.7100
-5.52%
 
SNGX Soligenix, Inc.
0.4150
-2.81%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
TCON TRACON Pharmaceuticals, Inc.
1.8100
+1.12%
 
KPTI Karyopharm Therapeutics Inc.
1.0600
0.00%